A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB–001), a humanized monoclonal antibody to amyloid β, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty pa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Black, Ronald S., Sperling, Reisa A., Safirstein, Beth, Motter, Ruth N., Pallay, Allan, Nichols, Alice, Grundman, Michael
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3715117/
https://ncbi.nlm.nih.gov/pubmed/20505438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WAD.0b013e3181c53b00
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk